Related Experiment Video
Updated: Jul 30, 2026
11:17
Multiplex Therapeutic Drug Monitoring by Isotope-dilution HPLC-MS/MS of Antibiotics in Critical Illnesses
Published on: August 30, 2018
A process for interpreting data on adverse drug events: determining optimal target levels
1Division of Accreditation Operations, Joint Commission on Accreditation of Healthcare Organizations, Oakbrook Terrace, Illinois 60181, USA.
Clinical Therapeutics
|January 23, 1999
Summary
The Joint Commission on Accreditation of Healthcare Organizations (JCAHO) plays a key role in postmarketing drug surveillance by guiding healthcare organizations in responding to adverse drug events (ADEs). This ensures better patient safety and reduces ADE incidence and severity.
Area of Science:
- Healthcare Administration
- Pharmacovigilance
- Patient Safety
Background:
- The Joint Commission on Accreditation of Healthcare Organizations (JCAHO) accredits healthcare facilities using performance standards.
- JCAHO's role extends to postmarketing drug surveillance, focusing on organizational response to adverse drug events (ADEs).
Purpose of the Study:
- To discuss the role of JCAHO in mitigating the impact of adverse drug events within accredited healthcare organizations.
- To explore how JCAHO standards influence the review and response to significant ADEs.
Main Methods:
- Literature review of JCAHO standards and their application to pharmacovigilance.
- Analysis of JCAHO's framework for reporting and managing ADEs in healthcare settings.
Main Results:
- JCAHO accreditation standards implicitly guide ADE surveillance and management.
- Healthcare organizations accredited by JCAHO are prompted to establish protocols for identifying and responding to ADEs.
Conclusions:
- JCAHO significantly influences healthcare organizations' approaches to reducing ADEs.
- Effective implementation of JCAHO guidelines can lead to decreased incidence and severity of adverse drug events, enhancing patient safety.
Related Concept Videos
01:19Pharmacovigilance
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
01:24Rational Dosage Regimen: Maintenance Dose and Loading Dose
A rational dosage regimen considers a drug's pharmacokinetics, including its absorption, distribution, metabolism, and elimination from the body. By understanding these factors, the appropriate dosage can be determined, and the dosing schedule can be designed to achieve and maintain the desired therapeutic effect while minimizing adverse effects.
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
In most cases, drugs are administered repetitively or infused continuously to maintain a steady-state concentration in the body. At a steady state,...
01:16Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood at designated intervals to ensure the drug concentration stays within a therapeutic range. This monitoring is crucial for optimizing individual dosage regimens, enhancing therapeutic efficacy, and minimizing drug-related toxicity. TDM is vital for drugs with narrow therapeutic windows, significant variability in pharmacokinetics, and a clear correlation between plasma levels and...
01:29Therapeutic Drug Monitoring: Affecting Factors
Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
01:26Therapeutic Drug Monitoring: Drug Analysis Methods
Therapeutic Drug Monitoring (TDM) is a clinical practice that measures specific drug levels in a patient's blood or body tissues to tailor drug therapy effectively. This monitoring is critical for managing drugs with narrow therapeutic indices like digoxin and phenytoin, ensuring they are both safe and effective. For instance, monitoring theophylline levels in asthma patients involves precision and sensitivity to adjust doses according to individual responses to therapy, ensuring efficacy and...
01:15Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).